Prescription drug · ANDA
Pyquvi (deflazacort) NDC 73289-0089
Deflazacort 22.75 mg/mL · Suspension · Oral · Aucta Pharmaceuticals, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 73289-0089-1 | 73289008901 | 13 mL in 1 BOTTLE (73289-0089-1)Marketed from Jun 30, 2025 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Pyquvi
- Generic name (nonproprietary)
- deflazacort
- Active ingredients
- Deflazacort — 22.75 mg/mL
- Dosage form
- Suspension
- Route
- Oral
- Labeler
- Aucta Pharmaceuticals, Inc.
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 219417
- Marketing start
- Listing expires
- Other FDA classes
- Corticosteroid Hormone Receptor Agonists (Mechanism)
- Identifiers
- Product ID 73289-0089_39853cd7-c033-848f-e063-6294a90a49e4SPL ID 39853cd7-c033-848f-e063-6294a90a49e4SPL set ID 39854f19-d8be-6438-e063-6394a90a9422RxCUI 1870964, 2719198UNII KR5YZ6AE4B
- Pharmacologic class
- Corticosteroid
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N473289008901followed by a unit qualifier and the quantityPackage 73289-0089-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
PYQUVI is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. Additional pediatric use information is approved for PTC Therapeutics, Inc.'s Emflaza ® (deflazacort) oral suspension. However, due to PTC Therapeutics, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information. PYQUVI is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older ( 1 )
Excerpt only. Read the full label for complete information.